Menu
Fechar
hrs4r
Quiero donar

ANA GARZO MORENO

Hematología
Firma
ANA GARZO-MORENO
Posición
Investigadors/es Col·laboradors/es
Investigadores/as Colaboradores/as
Publicacions

Publicacions

Moreno, A, Arostegui, IC, Garzo, A, Abril, L, Escoda, L, Casas, A, Ibarra, G, Cañamero, E, Cabezudo, E, Ortin, X, Biosca, C, Viñas, J, Bedoya, T, Giménez, A, Blanco, C, Botafogo, V, Izquierdo, M, Sarrà, J, Montes, YG, Balari, AS, Oriol, A

Impact of Cumulative and Relative Dose Intensity of Bortezomib, Lenalidomide, and Dexamethasone (VRD) on Depth and Duration of Response in Newly Diagnosed Multiple Myeloma (MM)

Clinical Lymphoma Myeloma & Leukemia, 2025, 25
Medina, AC, Arostegui, IC, Garzo, A, Abril, L, Escoda, L, Cañamero, E, Cabezudo, E, Ortín, X, Biosca, C, Viñas, J, Bedoya, T, Giménez, A, Sarrà, J, Montes, YG, Balarí, AS, Oriol, A

Severe Infections in Newly Diagnosed Multiple Mieloma Patients Treated Frontline with Bortezomib, Lenalidomide and Dexamethasone (VRD) in Four Reference Centers

Clinical Lymphoma Myeloma & Leukemia, 2025, 25, 263-264
Gonzalez-Montes, Y, Osca-Gelis, G, Rodriguez-Romanos, R, Villavicencio, A, González-Bártulos, M, Llopis, F, Clapes, V, Oriol, A, Sureda, A, Escoda, L, Sarrà, J, Garzó, A, Lloveras, N, Gómez, B, Granada, I, Gallardo, D

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2024, 15, 1252445-1252445 dx.doi.org/10.3389/fimmu.2024.1252445
Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2023, 14, 1158105-1158105 dx.doi.org/10.3389/fimmu.2023.1158105

Formulari de contacte

Conoce el IDIBGI!

 menu